Boiron S.A.

Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
  • TickerBOI
  • ISINFR0000061129
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Boiron: 1 director sold

A director at Boiron sold 17,796 shares at 33.372EUR and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Christophe-Raphaël Ganet

Boiron : Boiron and Rocal appeal to the Conseil d’Etat against the decision to end reimbursements for homeopathy

>Homeopathic groups attempt a legal appeal - Subsequent to the decision to stop reimbursing homeopathic treatments from January 2021 (see our previous comments and our report of 25/10/2019), Boiron and Rocal have lodged an appeal with the Conseil d’Etat.The main effect of the decision announced in July by the French health authority (Haute Autorité de Santé, HAS) (reduction in the reimbursement rate from 30% to 15% at 1 January 2020 and then to 0% at 1 January 20...

Aurelien Sivignon ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier

ODDO BHF Small & MIDCAP MORNING NEWS - 12/10/2019

...

Aurelien Sivignon ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier

ODDO BHF Small & MIDCAP MORNING NEWS - 10/12/2019

...

Christophe-Raphaël Ganet

Boiron : Boiron et Rocal déposent un recours au conseil d’Etat contre la décision de déremboursement de l’homéopathie

>Les laboratoires d’homéopathie tentent un recours judiciaire - Pour faire suite à la décision de dérembourser de l’homéopathie à partir de janvier 2021 (relire nos précédents commentaires et notre étude du 25/10/2019), les laboratoires Boiron et Rocal formalisent un recours auprès du conseil d’Etat.La décision prononcée en juillet, par la Haute Autorité de Santé (baisse de 30% à 15% du taux de remboursement au 1er janvier 2020 puis 0% au 1er janvier 2021) a eu p...

Christophe-Raphaël Ganet

Boiron : Boiron and Rocal appeal to the Conseil d’Etat against the decision to end reimbursements for homeopathy

>Homeopathic groups attempt a legal appeal - Subsequent to the decision to stop reimbursing homeopathic treatments from January 2021 (see our previous comments and our report of 25/10/2019), Boiron and Rocal have lodged an appeal with the Conseil d’Etat.The main effect of the decision announced in July by the French health authority (Haute Autorité de Santé, HAS) (reduction in the reimbursement rate from 30% to 15% at 1 January 2020 and then to 0% at 1 January 20...

Christophe-Raphaël Ganet

Boiron : Boiron et Rocal déposent un recours au conseil d’Etat contre la décision de déremboursement de l’homéopathie

>Les laboratoires d’homéopathie tentent un recours judiciaire - Pour faire suite à la décision de dérembourser de l’homéopathie à partir de janvier 2021 (relire nos précédents commentaires et notre étude du 25/10/2019), les laboratoires Boiron et Rocal formalisent un recours auprès du conseil d’Etat.La décision prononcée en juillet, par la Haute Autorité de Santé (baisse de 30% à 15% du taux de remboursement au 1er janvier 2020 puis 0% au 1er janvier 2021) a eu p...

Christophe-Raphaël Ganet

Boiron : CA T3 toujours baissier – OC : 31.5 € vs 34 €

>T3 en repli de 8.2% - Les ventes du T3 sont en baisse de 8.2% à 143.1 M€, essentiellement en France où les ventes sont en recul de 13.9%. En Europe, la situation est contrastée avec une hausse de l’activité en Italie et une baisse en Espagne alors que les États-Unis enregistrent une progression sensible de ses ventes.A 9 mois, la baisse des ventes atteint -8.4% (-9.1% à tcc) dont HNC : -8.9% et OTC : -8%.Boiron s’attend à une poursuite de la baisse du CA su...

Christophe-Raphaël Ganet

Boiron : Sales continue to trend downwards in Q3 – TP lowered to € 31.5 vs € 34

>Q3 sales down 8.2% - Sales fell by 8.2% in Q3 to € 143.1m, especially in France where they dropped by 13.9%. Performances in Europe were mixed, with sales growing in Italy but decreasing in Spain, whereas sales in the US rose significantly.So sales over the full 9 months are down by -8.4% (-9.1% at constant currencies), of which -8.9% for NPH (non-proprietary homeopathy) and -8% for OTC (over the counter) medicines.Boiron expects sales to contin...

Christophe-Raphaël Ganet

Boiron : Can you do more with less?

In France, reimbursement of homeopathic treatments, which form Boiron's core business, will be completely discontinued as of 2021. In this report, we explore the likely impact on Boiron and the consequences on its business. Our forecasts are adjusted down (to more effectively factor in the reduced rate of reimbursement), as is our target price to € 31.5. - >The sword of Damocles has fallen - After several months of debate and an evaluation process conducted by the Hea...

Boiron: 1 director sold

A director at Boiron sold 17,796 shares at 33.372EUR and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members...

Aurelien Sivignon ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier

ODDO BHF Small & MIDCAP MORNING NEWS - 12/10/2019

...

Aurelien Sivignon ...
  • Christophe-Raphaël Ganet
  • Jean-François Granjon
  • Jeremy Garnier

ODDO BHF Small & MIDCAP MORNING NEWS - 10/12/2019

...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 10/25/2019

...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 25/10/2019

...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/10/2019

...

Thanks to a better fundamental star rating, BOIRON SA sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to BOIRON SA (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date November 22, 2019, the closing price was EUR 33.60 and its expected value was estimated at EUR 32.97.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Florian Béchaz

Boiron - Assemblée Générale des actionnaires du 16 mai 2019

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 7,69% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Jehanne Leroy

Proxy Report - 17/05/2018

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 8,33% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Boiron 2014

​Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch